Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging study of NNC 0113-0217 versus placebo and open-label liraglutide in type 2 diabetes
2007-003956-12Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2008
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of semaglutide in type 2 diabetes mellitus (T2DM) (7 arms), sponsored by Novo Nordisk. Primary endpoint: Change in HbA1c from baseline to end of treatment. Started Jan 2008; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2007-003956-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003956-12.